71803-59-3

Usage

Uses

Used in Pharmaceutical Industry:
3-HydroxyMethylpyrrole is used as a key intermediate in the synthesis of porphobilinogen and other trisubstituted pyrroles. These compounds are essential for the development of new pharmaceutical agents, particularly in the area of photodynamic therapy.
Used in Photodynamic Therapy:
3-HydroxyMethylpyrrole is used as a precursor for the synthesis of porphobilinogen and other trisubstituted pyrroles, which are crucial components in photodynamic therapy. Photodynamic therapy is a medical treatment that involves the use of light-sensitive compounds, such as porphyrins, to selectively target and destroy cancer cells or abnormal tissues when exposed to specific wavelengths of light. This application takes advantage of the unique photochemical properties of 3-HydroxyMethylpyrrole and its derivatives, making it a valuable component in the development of innovative therapeutic approaches for various medical conditions.

Upstream product

• 931-03-3 1H-pyrrole-3-carboxylic acid 
• 37964-17-3 pyrrole-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Selective mono-reduction of pyrrole-2,5 and 2,4-dicarboxylates

Pyrrole-2,5-dicarboxylates were rapidly and selectively reduced to the corresponding mono-alcohol using 3 eq of diisobutylaluminum hydride at 0°C. Pyrrole-2,4-dicarboxylate showed the same reactivity; however, the selectivity decreased with pyrrole-3,4-dicarboxylate. When the nitrogen atom of the pyrrole-2,5-dicarboxylate is protected with a benzyl group, selective mono-reduction does not occur. Considering that furan-2,5-dicarboxylates did not give the corresponding mono-alcohol under the same conditions, the unprotected nitrogen atom of pyrrole apparently plays an important role in this selective mono-reduction.

Identification of N-acylhydrazone derivatives as novel lactate dehydrogenase A inhibitors

Abstract Glycolysis is drastically increased in tumors and it is the main route to energy production with a minor use of oxidative phosphorylation. Among the key enzymes in the glycolytic process, LDH is emerging as one of the most interesting targets for the development of new inhibitors. In this context, in the present work, we carried out a virtual screening procedure followed by chemical modifications of the identified structures according to a "hit-to-lead" process. The effects of the new molecules were preliminary probed against purified human LDH-A. The compounds active at low micromolar level were additionally characterized for their activity on some cellular metabolic processes by using Raji human cell line. Within the series, 1 was considered the best candidate, and a more detailed characterization of its biological properties was performed. In Raji cells exposed to compound 1 we evidenced the occurrence of effects usually observed in cancer cells after LDH-A inhibition: reduced lactate production and NAD/NADH ratio, apoptosis. The flow cytometry analysis of treated cells also showed cell cycle changes compatible with effects exerted at the glycolytic level. Finally, in agreement with the data obtained with other inhibitors or by silencing LDH-A expression, compound 1 was found to increase Raji cells response to some commonly used chemotherapeutic agents. Taken together, all these finding are in support of the LDH-A inhibiting activity of compound 1.